Stock Analiz

Ardelyx, Inc. ARDX

Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026

$3.09Market cap $777M
Open the interactive analysis →

Ardelyx, Inc. (ARDX) is a healthcare company listed in the US with a market value of about $777M. In the twelve months to September 30, 2026 it had revenue of $468M and net income of -$55M, a net margin of -11.8%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 122% a year, a 5-year average ROIC of -34%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 42% below the current price.

About Ardelyx

Ardelyx is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $32M in 2014 to $407M in 2025, growth of about 26.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 52% over three years (dilution for shareholders). It spends 18% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E58.3
P/FCF—
P/S1.7
P/B4.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-2.1%
Shareholder yield0.0%
Intrinsic value vs. price−42%

Growth and quality

Revenue growth (1 yr)22.1%
Revenue growth (5 yrs, per year)121.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-355.1%
ROIC (5-yr avg.)-34.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$468M$407M$334M$124M$52M$10M$8M$5M$3M$42M—
Net income-$55M-$62M-$39M-$66M-$67M-$158M-$94M-$95M-$91M-$64M-$112M
Free cash flow-$16M-$44M-$46M-$90M-$70M-$154M-$82M-$77M-$71M-$68M-$97M
EPS (diluted)$-0.23$-0.26$-0.17$-0.30$-0.42$-1.52$-1.05$-1.47$-1.62$-1.36$-2.80
Net margin-11.8%-15.1%-11.7%-53.1%-128.8%-1566.5%-1245.7%-1797.8%-3502.0%-153.2%—
ROIC—-8.6%-6.8%-22.4%-37.4%-95.2%-40.0%-29.9%-42.8%-36.9%-46.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $12.50, 305% above the current price; targets range from $8.00 to $18.00; the consensus rating is “Strong buy”; expected EPS is $-0.20 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Ardelyx stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 42% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Ardelyx pay a dividend?

Not currently.

Is Ardelyx a good stock to buy?

We do not give buy or sell advice. Ardelyx scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.